© Reuters.
NEW YORK (Reuters) – A federal appeals court on Tuesday revived a lawsuit by a whistleblower who accused McKesson (NYSE:) of providing drug pricing tools to doctors to induce them to purchase drugs from the company.
The decision by the 2nd U.S. Circuit Court of Appeals in Manhattan restores claims by Adam Hart, a former McKesson business development executive.
By Kamal Choudhury and Christy Santhosh April 29 (Reuters) - on Wednesday reported better-than-expected quarterly revenue and profit, fueled by...
The good news? Looks like the market has decided that the war is over, and everything will get back to...
Ken Griffin, chief executive officer of Citadel Advisors LLC, at the Semafor World Economy Summit during the International Monetary Fund...
This article was written byFollowDaniel is an avid and active professional investor. He runs Crude Value Insights, a value-oriented...
MOSCOW, April 5 (Reuters) - Fuel leaked at Russia’s Baltic Sea port of Primorsk, while NORSI oil refinery caught fire...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.
